Showing results (21-30 of 82) with videos related to
Sort By:
Pageof 9
Cancer Investigation|May 29, 2007
A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabineSamit Hirawat, Jonathan Kolitz, Stuart M Lichtman, et al.Lymphatics|December 12, 2024
BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on MechanismHyunjoo Lee, Shabirul Haque, Rashmi Gupta, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2018
Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal ExpansionRashmi Gupta, Xiao J Yan, Jacqueline Barrientos, et al.Blood|August 9, 2007
CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cellsRajendra N Damle, Sonal Temburni, Carlo Calissano, et al.Hematology. American Society of Hematology. Education Program|November 25, 2003
Biology and treatment of chronic lymphocytic leukemiaMichael J Keating, Nicholas Chiorazzi, Bradley Messmer, et al.Blood|March 10, 2018
Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locusChiara Antoniani, Vasco Meneghini, Annalisa Lattanzi, et al.Leukemia & Lymphoma|September 22, 2015
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemiaMatt E Kalaycio, O George Negrea, Steven L Allen, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2019
Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response ProteinsRashmi Gupta, Wentian Li, Xiao J Yan, et al.Blood|August 10, 2012
T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patientsRajendra N Damle, Sonal Temburni, Taraneh Banapour, et al.Leukemia Research|July 4, 2024
Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AMLStephanie Boisclair, Edward Zhou, Phyu Naing, et al.Pageof 9